1llt: Difference between revisions
New page: left|200px<br /> <applet load="1llt" size="450" color="white" frame="true" align="right" spinBox="true" caption="1llt, resolution 3.10Å" /> '''BIRCH POLLEN ALLERG... |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:1llt.gif|left|200px]]<br /> | [[Image:1llt.gif|left|200px]]<br /><applet load="1llt" size="350" color="white" frame="true" align="right" spinBox="true" | ||
<applet load="1llt" size=" | |||
caption="1llt, resolution 3.10Å" /> | caption="1llt, resolution 3.10Å" /> | ||
'''BIRCH POLLEN ALLERGEN BET V 1 MUTANT E45S'''<br /> | '''BIRCH POLLEN ALLERGEN BET V 1 MUTANT E45S'''<br /> | ||
==Overview== | ==Overview== | ||
Specific allergy vaccination is an efficient treatment for allergic | Specific allergy vaccination is an efficient treatment for allergic disease; however, the development of safer vaccines would enable a more general use of the treatment. Determination of molecular structures of allergens and allergen-Ab complexes facilitates epitope mapping and enables a rational approach to the engineering of allergen molecules with reduced IgE binding. In this study, we describe the identification and modification of a human IgE-binding epitope based on the crystal structure of Bet v 1 in complex with the BV16 Fab' fragment. The epitope occupies approximately 10% of the molecular surface area of Bet v 1 and is clearly conformational. A synthetic peptide representing a sequential motif in the epitope (11 of 16 residues) did not inhibit the binding of mAb BV16 to Bet v 1, illustrating limitations in the use of peptides for B cell epitope characterization. The single amino acid substitution, Glu(45)-Ser, was introduced in the epitope and completely abolished the binding of mAb BV16 to the Bet v 1 mutant within a concentration range 1000-fold higher than wild type. The mutant also showed up to 50% reduction in the binding of human polyclonal IgE, demonstrating that glutamic acid 45 is a critical amino acid also in a major human IgE-binding epitope. By solving the three-dimensional crystal structure of the Bet v 1 Glu(45)-Ser mutant, it was shown that the change in immunochemical activity is directly related to the Glu(45)-Ser substitution and not to long-range structural alterations or collapse of the Bet v 1 mutant tertiary structure. | ||
==About this Structure== | ==About this Structure== | ||
1LLT is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Betula_pendula Betula pendula]. Full crystallographic information is available from [http:// | 1LLT is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Betula_pendula Betula pendula]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1LLT OCA]. | ||
==Reference== | ==Reference== | ||
| Line 16: | Line 15: | ||
[[Category: Gajhede, M.]] | [[Category: Gajhede, M.]] | ||
[[Category: Ipsen, H.]] | [[Category: Ipsen, H.]] | ||
[[Category: Larsen, J | [[Category: Larsen, J N.]] | ||
[[Category: Mirza, O.]] | [[Category: Mirza, O.]] | ||
[[Category: Neerven, R | [[Category: Neerven, R J.Van.]] | ||
[[Category: Spangfort, M | [[Category: Spangfort, M D.]] | ||
[[Category: allergen]] | [[Category: allergen]] | ||
[[Category: pathogenesis related proteins]] | [[Category: pathogenesis related proteins]] | ||
''Page seeded by [http:// | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 13:46:07 2008'' | ||
Revision as of 11:46, 21 February 2008
|
BIRCH POLLEN ALLERGEN BET V 1 MUTANT E45S
Overview
Specific allergy vaccination is an efficient treatment for allergic disease; however, the development of safer vaccines would enable a more general use of the treatment. Determination of molecular structures of allergens and allergen-Ab complexes facilitates epitope mapping and enables a rational approach to the engineering of allergen molecules with reduced IgE binding. In this study, we describe the identification and modification of a human IgE-binding epitope based on the crystal structure of Bet v 1 in complex with the BV16 Fab' fragment. The epitope occupies approximately 10% of the molecular surface area of Bet v 1 and is clearly conformational. A synthetic peptide representing a sequential motif in the epitope (11 of 16 residues) did not inhibit the binding of mAb BV16 to Bet v 1, illustrating limitations in the use of peptides for B cell epitope characterization. The single amino acid substitution, Glu(45)-Ser, was introduced in the epitope and completely abolished the binding of mAb BV16 to the Bet v 1 mutant within a concentration range 1000-fold higher than wild type. The mutant also showed up to 50% reduction in the binding of human polyclonal IgE, demonstrating that glutamic acid 45 is a critical amino acid also in a major human IgE-binding epitope. By solving the three-dimensional crystal structure of the Bet v 1 Glu(45)-Ser mutant, it was shown that the change in immunochemical activity is directly related to the Glu(45)-Ser substitution and not to long-range structural alterations or collapse of the Bet v 1 mutant tertiary structure.
About this Structure
1LLT is a Single protein structure of sequence from Betula pendula. Full crystallographic information is available from OCA.
Reference
Dominating IgE-binding epitope of Bet v 1, the major allergen of birch pollen, characterized by X-ray crystallography and site-directed mutagenesis., Spangfort MD, Mirza O, Ipsen H, Van Neerven RJ, Gajhede M, Larsen JN, J Immunol. 2003 Sep 15;171(6):3084-90. PMID:12960334
Page seeded by OCA on Thu Feb 21 13:46:07 2008
